Conivaptan: Difference between revisions
CSV import |
CSV import Tag: Removed redirect |
||
| Line 1: | Line 1: | ||
{{Short description|A vasopressin receptor antagonist used in the treatment of hyponatremia}} | |||
[[File:Conivaptan_structure.svg|Structure of Conivaptan|thumb|right]] | |||
File: | '''Conivaptan''' is a [[vasopressin receptor antagonist]] used primarily in the treatment of [[hyponatremia]], a condition characterized by low levels of sodium in the blood. It is particularly effective in cases of euvolemic and hypervolemic hyponatremia, which are often associated with conditions such as [[syndrome of inappropriate antidiuretic hormone secretion]] (SIADH), [[congestive heart failure]], and [[cirrhosis]]. | ||
File:Conivaptan-3D-spacefill.png|Conivaptan | |||
==Mechanism of Action== | |||
Conivaptan works by antagonizing the effects of [[vasopressin]], a hormone that regulates water balance in the body. It specifically blocks the V1A and V2 subtypes of vasopressin receptors. The V2 receptor is primarily responsible for the antidiuretic effects of vasopressin in the kidneys, promoting water reabsorption. By inhibiting this receptor, conivaptan increases the excretion of free water, thereby correcting the sodium imbalance without causing significant loss of electrolytes. | |||
==Pharmacokinetics== | |||
Conivaptan is administered intravenously, as it has poor oral bioavailability. It is extensively metabolized in the liver, primarily by the [[cytochrome P450]] enzyme CYP3A4. The drug and its metabolites are excreted in the urine and feces. The half-life of conivaptan is approximately 5 to 8 hours, allowing for continuous infusion or repeated dosing to maintain therapeutic levels. | |||
==Clinical Use== | |||
Conivaptan is indicated for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients. It is not recommended for use in patients with hypovolemic hyponatremia, as it may exacerbate the condition. The drug is typically administered as a continuous intravenous infusion over several days, with careful monitoring of serum sodium levels to avoid overly rapid correction, which can lead to [[osmotic demyelination syndrome]]. | |||
==Adverse Effects== | |||
Common side effects of conivaptan include [[infusion site reactions]], [[hypotension]], [[hypokalemia]], and [[headache]]. Due to its metabolism by CYP3A4, conivaptan can interact with other drugs that are substrates, inhibitors, or inducers of this enzyme, necessitating careful consideration of potential drug interactions. | |||
[[File:Conivaptan-3D-spacefill.png|3D space-filling model of Conivaptan|thumb|left]] | |||
==Contraindications== | |||
Conivaptan is contraindicated in patients with known hypersensitivity to the drug or its components. It should not be used in patients with hypovolemic hyponatremia or in those with anuria. Caution is advised in patients with hepatic or renal impairment, as these conditions may affect the drug's metabolism and excretion. | |||
==Related Pages== | |||
* [[Hyponatremia]] | |||
* [[Vasopressin receptor antagonist]] | |||
* [[Syndrome of inappropriate antidiuretic hormone secretion]] | |||
* [[Congestive heart failure]] | |||
[[Category:Vasopressin receptor antagonists]] | |||
[[Category:Diuretics]] | |||
[[Category:Antidiuretic hormone receptor antagonists]] | |||
Latest revision as of 21:25, 4 March 2025
A vasopressin receptor antagonist used in the treatment of hyponatremia
Conivaptan is a vasopressin receptor antagonist used primarily in the treatment of hyponatremia, a condition characterized by low levels of sodium in the blood. It is particularly effective in cases of euvolemic and hypervolemic hyponatremia, which are often associated with conditions such as syndrome of inappropriate antidiuretic hormone secretion (SIADH), congestive heart failure, and cirrhosis.
Mechanism of Action[edit]
Conivaptan works by antagonizing the effects of vasopressin, a hormone that regulates water balance in the body. It specifically blocks the V1A and V2 subtypes of vasopressin receptors. The V2 receptor is primarily responsible for the antidiuretic effects of vasopressin in the kidneys, promoting water reabsorption. By inhibiting this receptor, conivaptan increases the excretion of free water, thereby correcting the sodium imbalance without causing significant loss of electrolytes.
Pharmacokinetics[edit]
Conivaptan is administered intravenously, as it has poor oral bioavailability. It is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme CYP3A4. The drug and its metabolites are excreted in the urine and feces. The half-life of conivaptan is approximately 5 to 8 hours, allowing for continuous infusion or repeated dosing to maintain therapeutic levels.
Clinical Use[edit]
Conivaptan is indicated for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients. It is not recommended for use in patients with hypovolemic hyponatremia, as it may exacerbate the condition. The drug is typically administered as a continuous intravenous infusion over several days, with careful monitoring of serum sodium levels to avoid overly rapid correction, which can lead to osmotic demyelination syndrome.
Adverse Effects[edit]
Common side effects of conivaptan include infusion site reactions, hypotension, hypokalemia, and headache. Due to its metabolism by CYP3A4, conivaptan can interact with other drugs that are substrates, inhibitors, or inducers of this enzyme, necessitating careful consideration of potential drug interactions.
Contraindications[edit]
Conivaptan is contraindicated in patients with known hypersensitivity to the drug or its components. It should not be used in patients with hypovolemic hyponatremia or in those with anuria. Caution is advised in patients with hepatic or renal impairment, as these conditions may affect the drug's metabolism and excretion.
